

RESEARCH ARTICLE

Open Access

Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma

Timo K Nykopp^{1,3}, Kirsi Rilla², Markku I Tammi², Raija H Tammi², Reijo Sironen¹, Kirsi Hämäläinen¹, Veli-Matti Kosma¹, Seppo Heinonen³, Maarit Anttila^{3*}

Abstract

Background: Hyaluronan accumulation correlates with the degree of malignancy in many solid tumor types, including malignant endometrial carcinomas. To elucidate the mechanism of hyaluronan accumulation, we examined the expression levels of the hyaluronan synthases (*HAS1*, *HAS2* and *HAS3*) and hyaluronidases (*HYAL1* and *HYAL2*), and correlated them with hyaluronan content and HAS1-3 immunoreactivity.

Methods: A total of 35 endometrial tissue biopsies from 35 patients, including proliferative and secretory endometrium (n = 10), post-menopausal proliferative endometrium (n = 5), complex atypical hyperplasia (n = 4), grade 1 (n = 8) and grade 2 + 3 (n = 8) endometrioid adenocarcinomas were divided for gene expression by real-time RT-PCR, and paraffin embedded blocks for hyaluronan and HAS1-3 cytochemistry.

Results: The mRNA levels of *HAS1-3* were not consistently changed, while the immunoreactivity of all HAS proteins was increased in the cancer epithelium. Interestingly, *HAS3* mRNA, but not *HAS3* immunoreactivity, was increased in post-menopausal endometrium compared to normal endometrium (p = 0.003). The median of *HYAL1* mRNA was 10-fold and 15-fold lower in both grade 1 and grade 2+3 endometrioid endometrial cancers, as compared to normal endometrium (p = 0.004-0.006), and post-menopausal endometrium (p = 0.002), respectively. *HYAL2* mRNA was also reduced in cancer (p = 0.02) and correlated with *HYAL1* (r = 0.8, p = 0.0001). There was an inverse correlation between *HYAL1* mRNA and the epithelial hyaluronan staining intensity (r = -0.6; P = 0.001).

Conclusion: The results indicated that *HYAL1* and *HYAL2* were coexpressed and significantly downregulated in endometrioid endometrial cancer and correlated with the accumulation of hyaluronan. While immunoreactivity for HASs increased in the cancer cells, tumor mRNA levels for HASs were not changed, suggesting that reduced turnover of HAS protein may also have contributed to the accumulation of hyaluronan.

Background

Cancer of the endometrium is the most common malignant tumor of the female genital tract and it typically affects postmenopausal women [1,2]. The prognosis of endometrial cancer is generally good, since the age-adjusted 5-year overall survival is 82% [3]. Although most patients are diagnosed at an early stage, i.e. disease confined to the uterus, still 20% of the cancers recur after primary treatment. Adjuvant treatment does not

prolong the overall survival, maybe because of inadequate patient selection. Therefore, new prognostic markers are needed. Molecular markers in endometrial cancer are still rather poorly defined [4].

It has been commonly recognized that development of human neoplasia is accompanied by changes in the extracellular matrix (ECM) which is particularly important in regulating tumor dissemination [5]. The glycosaminoglycan hyaluronic acid/hyaluronan (HA) is a ubiquitous component of the extracellular matrix (ECM).

Hyaluronan is an independent, unfavorable prognostic factor in another gynaecological malignancy, epithelial ovarian cancer [6], and a number of other

* Correspondence: Maarit.Anttila@uef.fi

³Institute of Clinical Medicine, Department of Obstetrics and Gynecology, University of Eastern Finland and Kuopio University Hospital, Kuopio Finland
Full list of author information is available at the end of the article

malignancies [7,8]. Hyaluronan and its receptor CD44 are both involved in the development and progression of endometrial cancer [9].

Hyaluronan can be produced in mammals by three hyaluronan synthase isoenzymes: HAS1, HAS2 and HAS3 [10]. *HAS* mRNA levels often correspond to the rate of hyaluronan synthesis, and are known to influence the content of hyaluronan in transplanted tumors [11]. Therefore, upregulation of *HAS* expression can contribute to the hyaluronan accumulation in tissues, and promote tumor growth and metastasis in experimental animals, in particular when coexpressed with hyaluronidase [12,13].

The catabolism of hyaluronan is more complex process [14]. Hyaluronan in the extracellular matrix can be partially fragmented by hyaluronidase activity or oxygen free radicals, and diffuse away through lymph. Alternatively, hyaluronan can be taken up by adjacent cells and be subject to lysosomal degradation in the tissue of origin [15]. The rate of hyaluronan catabolism may therefore be contributed by the formation of oxygen free radicals, access to lymph, local uptake by cells, and hyaluronidases.

There are 6 hyaluronidases in the human genome, two of them (*HYAL1* and *HYAL2*) are ubiquitous and characterized at protein level [16]. *HYAL1* and *HYAL2* have been shown to inhibit tumor growth *in vivo*, and it has been suggested that these two genes have major roles in the microenvironment of tumor cells [17]. Recent findings have suggested that depending on its concentration, *HYAL1* can function either as a tumor promoter or as a suppressor [18].

The major transcript of *HYAL3* is enzymatically inactive and appears to have only a supportive role in *HYAL 1* expression [19]. *HYAL 3* knockout mice do not display any evidence of hyaluronan accumulation [20]. Very little is known about *HYAL4*, but its expression is limited, and it might be a chondroitinase rather than hyaluronidase [16,21]. The expression of the *SPAM1* gene-encoded PH20 hyaluronidase is almost exclusively detected in testis and sperm, and shows activity in higher pH.

In an invasive bladder cancer cell line, blocking of *HYAL1* expression decreases tumor growth, inhibits tumor infiltration and decreases microvessel density [22]. Increased hyaluronidase expression has also been reported in prostate [18] and colon cancer [14], and in breast tumor metastases [23]. In contrast, recent findings have shown that the expression of *HYAL1* and *HYAL2* genes is significantly decreased in lung and kidney cancer samples [17]. Also experimental overexpression of *HYAL1* in a rat colon carcinoma cell line inhibits tumor growth and generates necrotic tumors [11].

We have found that the median concentration of hyaluronan is increased in malignant ovarian tumors

without hyaluronidase activation [24]. In further studies we have shown that significantly decreased *HYAL1* expression correlates with decreased hyaluronidase activity and elevated hyaluronan content of the tumors, while *HAS* expression was not as consistently associated to the accumulation of hyaluronan [25].

In this study we found that in the most common gynaecological malignancy, endometrial cancer, the accumulation of hyaluronan is also associated with decreased expression of hyaluronidase genes. Blocking the accumulation of hyaluronan might offer a new way of fighting against these diseases

Methods

Patients

A total of 35 endometrial tissue specimens from 35 patients were divided into 5 groups: proliferative and secretory endometrium (n = 10), post-menopausal proliferative endometrium (n = 5), complex atypical hyperplasia (n = 4), grade 1 (n = 8) and grade 2+3 (n = 8) endometrioid adenocarcinomas (Table 1). The normal endometrium tissue specimens were obtained from hysterectomies for nonmalignant diseases (e.g. leiomyoma or prolapse of uterus). The malignant tumors of endometrium were staged according to FIGO. The ethical committee of the Kuopio University Hospital has approved the study protocol and patients signed the informed consent.

Histology

Histological typing and grading were done according to the WHO classification [26,27]. Grade 2 and 3 cancers were combined into one subgroup.

Tissue samples

The tissue specimens collected in the operation room were prepared and evaluated by an experienced pathologist (KH). All the samples were collected and handled identically. Aliquots of the tissues were 1) placed in RNAlater® (Ambion, Austin, TX) for mRNA analyses; 2) fixed in 10% buffered formalin and embedded in paraffin.

RNA Extraction and cDNA Preparation

Samples were stored at -80°C until RNA preparation. The samples were frozen by liquid nitrogen and pulverized under pressure using a stainless steel cylinder and a piston. Total RNA was isolated using Trizol® Reagent (Invitrogen) according to manufacturer's protocol, quantified spectrophotometrically and its integrity confirmed by agarose electrophoresis, based on the appearance of the 18S and 28S RNA bands. First strand cDNA was synthesized from 2.5 µg of total RNA using High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA)

Table 1 Clinicopathological data of the tissue samples

Tissue type	Histology	No. Patients	Age at diagnosis [†]	FIGO stage		
				IB	IC	II
Normal endometrium	Proliferating	4	42 (42-45)			
	Secreting	6	48 (41-52)			
Postmenopausal	Proliferating	5	69 (57-75)			
Hyperplastic endometrium	Complex atypical	4	52 (45-68)			
Malignant endometrium	Endometrioid adenocarcinoma	Grade I	66 (46-76)	4	3	1
		Grade II	70 (63-81)	2	1	1
		Grade III	62 (41-81)	1	2	2
All patients		35				

[†] median (range).

according to manufacturer's protocol in a final volume of 50 µl.

Quantitative real-time RT-PCR

Real-time gene expression analysis of all target genes (*HYAL1*, *HYAL2*, *HAS1-3*) was performed using TaqMan® Gene Expression Assays (Applied Biosystems) according to manufacturer's instructions and as described previously [25]. The assay numbers for these genes were as follows: Hs00201046_m1 (*HYAL1*); Hs00186841_m1 (*HYAL2*); Hs00758053_m1 (*HAS1*); Hs00193435_m1 (*HAS2*); Hs00193436_m1 (*HAS3*); Hs99999909_m1 (*HPRT*).

The *HPRT1* gene we used for normalization was an accurate reference for the quantitative gene expression assays in clinical tumor samples [28]. Relative gene expression values were calculated as the ratio between the target gene and *HPRT1*, obtained for each sample from the standard curves.

Staining of HASs

The HAS immunostainings were performed as described previously [25]. Shortly, antigen retrieval was performed for *HAS1-3* staining by boiling for 3 × 5 min in a citrate buffer. Thereafter sections were treated for 5 min with 1% H₂O₂ to block endogenous peroxidase activity and incubated in 1% bovine serum albumin (BSA) in PBS for 30 min to block nonspecific binding. The sections were incubated overnight at 4°C with polyclonal antibodies for *HAS1* (2 µg/ml, sc-34021, Santa Cruz Biotechnology, inc., Santa Cruz, CA), *HAS2* (2 µg/ml, sc-34067, Santa Cruz) or *HAS3* (2 µg/ml sc-34204, Santa Cruz), diluted in 1% BSA. Sections were incubated for 1 hour with biotinylated antigoat antibody (1:1000, Vector Laboratories). The bound antibodies were visualized with the avidin-biotin peroxidase method (1:200, Vectastain Kit, Vector Laboratories), yielding a brown reaction product. The sections were counterstained with Mayer's hematoxylin. The staining intensity of *HAS1*, *HAS2* and *HAS3* was graded into three categories in the epithelium: negative

(n.d.), weak and moderate, and into two categories in the stroma: negative (n.d.) or weak. The percentage of positive area for each HAS was estimated both in stroma and epithelium.

Staining of Hyaluronan

Deparaffinized 5-µm tissue sections were stained for hyaluronan with our own preparation of biotinylated hyaluronan-binding complex (bHABC) as described in detail previously [24]. All samples were scored by an observer unaware of the clinical data (M.A.). The intensity of hyaluronan positivity in epithelium and in stroma was graded into three categories: 1 (weak); 2 (moderate); and 3 (strong) and the area percentage of the strongest hyaluronan expression in the whole tumor section was evaluated separately in epithelium and stroma.

Statistical methods

Statistical analyses were carried out using SPSS 16.0 for Windows (SPSS, Chicago, IL). Differences between the patient groups were first analysed by using a non-parametric Kruskal-Wallis test, and when found significant a non-parametric Mann - Whitney U-test was used for further comparisons between the patient groups. Correlations between gene expression data and hyaluronan staining and immunostaining scores were analysed by using the Spearman's correlation test. A Chi-square test was used to analyse the association of hyaluronan staining and immunostaining scores. We considered p-value ≤ 0.01 as statistically significant.

Results

Expression of *HAS1*, *HAS2* and *HAS3*

mRNA from normal endometrium and different tissue lesions were analyzed by real-time RT-PCR for the hyaluronan synthases *HAS1*, *HAS2*, and *HAS3* (figure 1). Transcripts of *HAS1* were detected at such a low level that reliable quantitation was not consistently possible. Expression of *HAS2* was not significantly changed in




Figure 1 *HAS 2-3* mRNA expression in human endometrium and its lesions. Relative mRNA levels of A) *HAS2* and B) *HAS3* in different tissues. The boxes show the ranges between 25th and 75th percentiles, with a horizontal line at the median value. The whiskers extend to the 10th and 90th percentiles. The open circles represent the outlier values. NE = normal pre-menopausal endometrium, PME = post-menopausal proliferative endometrium, CAH = complex atypical hyperplasia, G1 = grade 1 endometrioid endometrial adenocarcinoma, G2 + 3 = grade 2 + 3 endometrioid endometrial adenocarcinoma.

malignant tumors or the postmenopausal or hyperplastic tissues as compared to normal endometrium (figure 1A). On the other hand *HAS3* expression was increased over 4-fold in post-menopausal endometrium ($p = 0.003$) compared to pre-menopausal endometrium. We also noticed that *HAS3* expression was also elevated (1.5-fold increase) in grade 1 malignant tumors compared to normal endometrium, this finding being borderline significant ($p = 0.033$) (figure 1B).

Expression of *HYAL1* and *HYAL2*

Since the two ubiquitous hyaluronidases, *HYAL1* and *HYAL2*, were likely to account for most or all of the hyaluronidase activity, we quantified their mRNA levels by real-time RT-PCR (figure 2). There was a significant decline in *HYAL1* expression from normal endometrium to the cancers (Kruskal Wallis $p = 0.002$). A 10-fold higher expression of median *HYAL1* mRNA expression was found in normal endometrium as compared to both grade 1 and grade 2 + 3 malignant tumors, and over 15-fold higher values were seen in normal post-menopausal endometrium (figure 2A). Similar trend was noticed between *HYAL2* expression in grade 1 and grade 2 + 3 cancers compared to normal endometrium, this difference being borderline significant (figure 2B). There was also a strong and statistically significant correlation between *HYAL1* and *HYAL2* expressions ($r = 0.8$; $p < 0.0001$)

HAS immunostainings

The epithelial intensities of HAS1 (figure 3A,B), HAS2 (figure 3C,D) and HAS3 (figure 3E,F) immunostainings were significantly stronger in endometrial tumors compared to normal endometrium ($p = 0.001$, $p = 0.004$ and $p = 0.003$, respectively) (table 2). However, the staining intensities did not correlate with tumor grade. Epithelial hyaluronan staining intensity was associated with HAS2 epithelial staining intensity ($p = 0.009$). No significant correlations were found between the mRNA levels and immunohistochemical protein scores of HAS1-3. On the other hand, an inverse correlation of *HYAL1* expression with HAS3 epithelial staining intensity was found ($r = -0.5$, $p = 0.004$).

Hyaluronan content

The level of hyaluronan accumulation in the present set of lesions was scored from tissue sections using a biotinylated probe that specifically binds hyaluronan [6] (figure 3G,H). This histological assay closely correlates with biochemical quantitation of hyaluronan [24]. Epithelial and also stromal hyaluronan intensity score was significantly elevated ($p = 0.0001$ and $p = 0.006$ respectively) in the endometrioid endometrial tumors compared to normal endometrium (table 3).

Relationship between hyaluronan accumulation and *HAS* and *HYAL* mRNA levels

No significant correlations were found between the level of *HAS2* or *HAS3* mRNA and the hyaluronan content. Instead, *HYAL1* transcript levels showed a significant inverse correlation with epithelial ($r = -0.6$, $p = 0.001$) and stromal hyaluronan staining score ($r = -0.4$, $p = 0.01$). *HYAL2* transcript levels also correlated with epithelial hyaluronan staining score ($r = -0.4$, $p = 0.01$).

Discussion

Hyaluronan synthase and hyaluronidase mRNA levels were quantitated for the first time in a set of sample groups from normal endometrium, post-menopausal endometrium, endometrial hyperplasia and endometrioid endometrial tumors.

HAS mRNA expression and immunohistochemistry in endometrioid endometrial cancer

Except for a trend of *HAS3* increase in grade 1 carcinomas, we did not find a clear pattern of increased *HAS1-3* mRNA in endometrial cancer, as compared to normal endometrium. This finding is somewhat similar to the enhanced *HAS3* mRNA level observed in benign, but not in malignant ovarian tumors [25]. On the other hand, *HAS3* mRNA was increased in proliferating post-menopausal endometrium, and has been suggested to promote the growth of bladder carcinoma cells [29]. Nevertheless, our results suggested that transcriptional upregulation of *HAS* gene expression was not the main contributor to the increased hyaluronan content of these tumors.

Despite minor changes in mRNAs, the immunoreactivity for all HASs was stronger in cancer cells compared to normal endometrium, although the density of the stainings did not significantly correlate with tumor grade. A similar discordance between the levels of *HAS* mRNA and HAS immunoreactivity was earlier found in ovarian cancer [25]. Curiously, the statistical significance for the cancer-associated increase of HAS immunoreactivity was strongest for HAS1 although real-time RT-PCR suggested very low transcription of this gene. As in the present study, Yabushita et al. [30] found that HAS1 immunoreactivity showed a strong association with endometrial cancer.

HAS2 is the only *HAS* gene which deletion causes a clear (lethal) phenotype [31], and it has been suggested to be most important for hyaluronan synthesis. In line with this idea, the immunohistochemical signal of epithelial HAS2 correlated with the staining score of epithelial HA.

Since the *HAS* gene expressions in tumor tissues poorly correlated with the content of the respective




Figure 2 *HYAL 1-2* mRNA expression in human endometrium and its lesions. Relative mRNA levels of A) *HYAL1* and B) *HYAL2* in different tissues. The boxes show the ranges between 25th and 75th percentiles, with a horizontal line at the median value. The whiskers extend to the 10th and 90th percentiles. NE = normal pre-menopausal endometrium, PME = post-menopausal proliferative endometrium, CAH = complex atypical hyperplasia, G1 = grade 1 endometrioid endometrial adenocarcinoma, G2 + 3 = grade 2 + 3 endometrioid endometrial adenocarcinoma.




Figure 3 HAS 1-3 immunoreactivity and HA-staining in normal and neoplastic human endometrium. Immunostaining of HAS1 (A, B), HAS2 (C, D), HAS3 (E, F) and HA (G, H) in normal human endometrium (A, C, E, G) and in grade 2 endometrioid endometrial carcinoma tissue sections (B, D, F, H). The brown color (DAB) indicates HAS (A-F) or HA (G, H), and blue color (haematoxylin) indicates nuclei. A-F: 200x original magnification. G, H: 100x original magnification.

Table 2 Hyaluronan staining in human endometrium and its lesions

	HA-staining intensity Epithelium*				HA-staining intensity Stroma*			
	n.d.	weak	moderate	strong	n.d.	weak	moderate	strong
Normal n = 9	9	0	0	0	0	0	9 (60%; 10-90%)	0
Proliferating pm [†] n = 5	5	0	0	0	0	3	1 (30%)	1 (100%)
Hyperplasia # n = 2	0	1 (5%)	1 (40%)	0	0	1 (40%)	0	1 (30%)
Grade 1 † n = 8	1	0	5 (2-5%)	2 (5-10%)	0	0	5 (70%; 20-80%)	3 (80%; 50-100%)
Grade 2+3 ‡ n = 8	1	0	4 (15%; 10-60%)	3 (30%; 20-30%)	0	0	2 (50-80%)	6 (80%; 20-90%)

* num. of samples with % of positive cells (% in median; range when necessary).

n.d. = not detected/negative.

complex atypical hyperplasia.

†pm = post-menopausal.

‡ endometrioid endometrial adenocarcinoma.

HAS proteins, as suggested by immunocytochemistry, the turnover of the HAS proteins should become slower in cancer cells. The time of functional work life of the HAS proteins in tissues was not known, but if extended, it may have had a major influence on hyaluronan synthesis.

Decreased expression of *HYAL1* and *HYAL2* mRNA and association to hyaluronan accumulation

The present findings of decreased *HYAL1* and *HYAL2* mRNA in endometrial cancer are consistent with the results we have recently shown in ovarian cancer [25]. Our findings are also similar to those of lung and kidney cancer samples in which a major down-regulation of *HYAL1* and *HYAL2* genes has been shown [17]. Our findings in endometrial and ovarian cancer are in contrast to reports on prostate and bladder tumors in which increased *HYAL1* protein and mRNA expression is associated with advanced disease and unfavorable prognosis [32,18,22]. One hypothesis to solve this contradiction between different types of cancers is that malignancies arising from different cell types use different strategies to progress and evolve. The relative importance of the opposite roles of hyaluronidase function in a particular type of cancer probably determines the outcome. The expression level is also important since *HYAL1* can either promote or suppress malignant growth in a single cell type, depending on the resulting enzyme activity [18].

HYAL1, a tumor suppressor

HYAL1 and *HYAL2* genes are located in 3p21.3 chromosome region, where allelic imbalance is frequent [33,14]. In the present study we noticed a strong correlation between *HYAL1* and *HYAL2* mRNA expression. It is possible that in endometrial cancer the *HYAL* mRNA

expression depends on the status of the chromosome 3p21.3 locus, and the decreased expression of *HYAL1* and *HYAL2* may be explained by concomitant deletions of these closely mapped genes. One theory to explain why decreased expression of hyaluronidase genes could lead to the development of cancer is *HYAL1* and its role in apoptosis. High *HYAL1* activity can result in apoptosis by increasing the expression of *WOX1* (WW domain-containing oxidoreductase, *WWOX*) [22]. *WOX1* causes mitochondrial permeabilization and is an essential partner of *p53* in cell death [34]. Hyaluronidase can also cause apoptosis by inducing *NAD*⁺-linked 15-hydroxyprostaglandin dehydrogenase (15-PDGH), an enzyme that degrades prostaglandins and promotes apoptosis in lung carcinoma cells [35]. Furthermore, the high molecular mass hyaluronan that occupies cell surface *CD44* receptors maintains *p*-Akt and *PI3K* dependent signals that prevent cancer cell apoptosis, while hyaluronidase, and the oligosaccharides created by hyaluronidase, block these cell survival signals [36]. It has also been recently demonstrated that ectopic expression of all three different somatic hyaluronidases (*HYAL1*, *HYAL2* and *HYAL3*) induce granulosa cell apoptosis [37].

Conclusion

The results indicated that *HYAL1* and *HYAL2* were coexpressed and significantly downregulated in endometrioid endometrial cancer and correlated with the accumulation of hyaluronan. The expression of *HAS1-3* mRNA is not elevated in endometrioid endometrial cancer while their immunoreactivity is elevated, suggesting cancer-associated changes in HAS protein turnover.

Abbreviations

HYAL: hyaluronidase; *HAS*: hyaluronan synthase; FIGO: International Federation of Gynecologists and Obstetrics.

Table 3 Immunostaining of HAS1, HAS2 and HAS3 in human endometrium and its lesions

	HAS1 staining intensity*			HAS2 staining intensity*			HAS3 staining intensity*		
	Epithelium	Stroma	Epithelium	Epithelium	Stroma	Epithelium	Stroma	Epithelium	Stroma
Normal n = 10	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
Proliferating pm [†] n = 5	4 (2 (10-25%))	3 (5-50%)	7 (5-10%)	0	0	0	0	5 (10-20%)	9 (10%)
Hyperplasia # n = 4	5 (0)	5 (0)	5 (0)	1 (2 (10-25%))	1 (10%)	1 (50%)	1 (50%)	5 (0)	5 (0)
Grade 1 † n = 8	1 (3 (5-25%))	3 (25-50%)	2 (5-25)	2 (5 (5-25))	2 (5%)	1 (50%)	8 (0)	2 (10%)	3 (25%)
Grade 2 + 3 † n = 8	0 (2 (25-50%))	6 (5-50%)	0 (5 (5-50%))	0 (0)	0 (0)	3 (5-50)	7 (1 (5%))	3 (10-20%)	8 (0)

* num. of samples with % of positive cells (% in median; range when necessary).

n.d. = not detected/negative.

complex atypical hyperplasia.

†pm = post-menopausal.

endometrioid endometrial adenocarcinoma.

Acknowledgements

We thank Mrs. Helena Kemiläinen, Mrs. Eija Rahunen and Mr. Kari Kotikumpu for expert technical assistance

This work was supported by grants from The Academy of Finland (MT), Finnish Cancer Foundation (RT, V-MK), The Finnish Cancer Institute (MA), The Finnish Medical Foundation (MA) and EVO Funds of the Kuopio University Hospital (TN, MT, V-MK, MA).

Author details

¹Institute of Clinical Medicine, Department of Pathology and Forensic Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland. ²Institute of Biomedicine, Department of Anatomy, University of Eastern Finland, Kuopio, Finland. ³Institute of Clinical Medicine, Department of Obstetrics and Gynecology, University of Eastern Finland and Kuopio University Hospital, Kuopio Finland.

Authors' contributions

TN performed the RNA extraction and RT-QPCR analyses, performed statistical analyses and drafted the manuscript. KR analysed the HAS staining and contributed to the manuscript. MT participated in design of the study and helped to draft the manuscript. KH contributed to pathological analysis of the tissue samples and helped to draft the manuscript. RT, RS, V-MK, and SH participated in design of the study and helped to draft the manuscript. MA conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 10 May 2010 Accepted: 27 September 2010

Published: 27 September 2010

References

1. Connelly PJ, Alberhasky RC, Christopherson WM: **Carcinoma of the endometrium. III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma.** *Obstet Gynecol* 1982, **59**:569-575.
2. Landis SH, Murray T, Bolden S, Wingo PA: **Cancer statistics, 1999.** *CA Cancer J Clin* 1999, **49**:8-31, 1.
3. Parkin DM, Bray F, Ferlay J, Pisani P: **Global cancer statistics, 2002.** *CA Cancer J Clin* 2005, **55**:74-108.
4. Engelsens IB, Akhlen LA, Salvesen HB: **Biologic markers in endometrial cancer treatment.** *APMIS* 2009, **117**:693-707.
5. Gui GP, Puddefoot JR, Vinson GP, Wells CA, Carpenter R: **Altered cell-matrix contact: a prerequisite for breast cancer metastasis?** *Br J Cancer* 1997, **75**:623-633.
6. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM: **High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer.** *Cancer Res* 2000, **60**:150-155.
7. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI: **Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan.** *Semin Cancer Biol* 2008, **18**:288-295.
8. Toole BP, Wight TN, Tammi MI: **Hyaluronan-cell interactions in cancer and vascular disease.** *J Biol Chem* 2002, **277**:4593-4596.
9. Afify AM, Craig S, Paulino AF, Stern R: **Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium.** *Ann Diagn Pathol* 2005, **9**:312-318.
10. Weigel PH, Hascall VC, Tammi M: **Hyaluronan synthases.** *J Biol Chem* 1997, **272**:13997-14000.
11. Jacobson A, Rahmanian M, Rubin K, Heldin P: **Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors.** *Int J Cancer* 2002, **102**:212-219.
12. Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB: **Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.** *Cancer Res* 2008, **68**:483-491.
13. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA: **Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.** *Am J Pathol* 2009, **174**:1027-1036.

14. Stern R: **Hyaluronan metabolism: a major paradox in cancer biology.** *Pathol Biol (Paris)* 2005, **53**:372-382.
15. Tammi R, Rilla K, Pienimäki JP, MacCallum DK, Hogg M, Luukkonen M, Hascall VC, Tammi M: **Hyaluronan enters keratinocytes by a novel endocytic route for catabolism.** *J Biol Chem* 2001, **276**:35111-35122.
16. Csoka AB, Frost GI, Stern R: **The six hyaluronidase-like genes in the human and mouse genomes.** *Matrix Biol* 2001, **20**:499-508.
17. Wang F, Grigorieva EV, Li J, Senchenko VN, Pavlova TV, Anedchenko EA, Kudryavtseva AV, Tsimanis A, Angeloni D, Lerman MI, Kashuba VI, Klein G, Zabarovsky ER: **HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro.** *PLoS One* 2008, **3**:e3031.
18. Lokeshwar VB, Cervinka WH, Isoyama T, Lokeshwar BL: **HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor.** *Cancer Res* 2005, **65**:7782-7789.
19. Hemming R, Martin DC, Slominski E, Nagy JJ, Halayko AJ, Pind S, Triggs-Raine B: **Mouse Hyal3 encodes a 45- to 56-kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells.** *Glycobiology* 2008, **18**:280-289.
20. Atmuri V, Martin DC, Hemming R, Gutsol A, Byers S, Sahebjam S, Thliveris JA, Mort JS, Carmona E, Anderson JE, Dakshinamurti S, Triggs-Raine B: **Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation.** *Matrix Biol* 2008, **27**:653-660.
21. Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T, Markowitz S, Willson J, Sy MS: **Expression of hyaluronidase by tumor cells induces angiogenesis in vivo.** *Proc Natl Acad Sci USA* 1996, **93**:7832-7837.
22. Lokeshwar VB, Cervinka WH, Lokeshwar BL: **HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion.** *Cancer Res* 2005, **65**:2243-2250.
23. Bertrand P, Girard N, Duval C, d'Anjou J, Chauzy C, Menard JF, Delpèch B: **Increased hyaluronidase levels in breast tumor metastases.** *Int J Cancer* 1997, **73**:327-331.
24. Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, Kosma VM: **Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors.** *Cancer Res* 2002, **62**:6410-6413.
25. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hamalainen K, Heikkinen AM, Komulainen M, Kosma VM, Anttila M: **Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content.** *BMC Cancer* 2009, **9**:143.
26. Karseladze AI: **WHO histological classification of ovarian tumors, Geneva, 1999.** In *Arkh Patol* Edited by: Scully RE, Sobin LH 2005, , **Suppl**: 1-64.
27. Tavassoli FA, Devilee P: **World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of the Breast and Female Genital Organs.** Lyon: IARC press, 1 2003, 217-232.
28. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN: **Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.** *Lab Invest* 2005, **85**:154-159.
29. Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L: **Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells.** *Cancer Res* 2001, **61**:5207-5214.
30. Yabushita H, Kishida T, Fusano K, Kanyama K, Zhuo L, Itano N, Kimata K, Noguchi M: **Role of hyaluronan and hyaluronan synthase in endometrial cancer.** *Oncol Rep* 2005, **13**:1101-1105.
31. Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro A Jr, Kubalak S, Klewer SE, McDonald JA: **Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme.** *J Clin Invest* 2000, **106**:349-360.
32. Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A, Hennenlotter J, Duncan RC, Soloway MS, Jorda M, Kuczyk MA, Stenzl A, Lokeshwar VB: **HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.** *Eur Urol* 2010, **57**:86-93.
33. Tuhkanen H, Anttila M, Kosma VM, Yla-Herttuala S, Heinonen S, Kuronen A, Juhola M, Tammi R, Tammi M, Mannermaa A: **Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p.** *Int J Cancer* 2004, **109**:247-252.
34. Chang NS, Pratt N, Heath J, Schultz L, Sleva D, Carey GB, Zevotek N: **Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.** *J Biol Chem* 2001, **276**:3361-3370.
35. Ding Y, Tong M, Liu S, Moscow JA, Tai HH: **NAD⁺-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.** *Carcinogenesis* 2005, **26**:65-72.
36. Ghatak S, Misra S, Toole BP: **Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.** *J Biol Chem* 2002, **277**:38013-38020.
37. Orimoto AM, Dumaresq-Doiron K, Jiang JY, Tanphaichitr N, Tsang BK, Carmona E: **Mammalian hyaluronidase induces ovarian granulosa cell apoptosis and is involved in follicular atresia.** *Endocrinology* 2008, **149**:5835-5847.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2407/10/512/prepub>

doi:10.1186/1471-2407-10-512

Cite this article as: Nykopp et al.: Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma. *BMC Cancer* 2010 **10**:512.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

